Professor John Appleby, Chief Economist at the King's Fund, joins panel of THE ASTELLAS INNOVATION DEBATE 2013
CHERTSEY, England, November 7, 2013 /PRNewswire/ --
The Age Crunch - facts, fears and the future
Chaired by Lord Robert Winston
Royal Institution of Great Britain, Tuesday 19th November 2013, 7pm
To be webcast live:http://www.innovationdebate.com
ENGLAND, Surrey
Leading health economist Professor John Appleby will be joining a panel of internationally recognised experts for the 2nd Astellas Innovation Debate: The Age Crunch - facts, fears and the future, taking place on 19th November at the Royal Institution of Great Britain. Following the success of the inaugural Astellas Innovation Debate, staged at the Royal Society in November last year and focusing on how to nurture the scientific innovators of the future, this year's debate moves the spotlight from young scientists to the ageing population - an issue of decisive and urgent importance.
Watch the video of Professor John Appleby discussing the challenges of an ageing population http://www.youtube.com/watch?v=U9slXcvy6iM
Professor John Appleby, who has been the Chief Economist at the King's Fund since 1998 and is a visiting professor at the Department of Economics at City University, London, commented: "Ageing is often framed in a negative light, seen as placing unsustainable pressure on health services. But, in reality, its impact on NHS costs is less dramatic than might be assumed. Increases in life expectancy extend the number of years of healthy life, so, rather than increasing healthcare costs per se, they tend simply to defer costs associated with death. However, in order to cater better for the health needs of this changing demographic, we do urgently need to examine the way our care services are organised and funded - otherwise this challenge may well turn into a crisis."
Joining Professor John Appleby on the panel will be Nobel prize-winning biologist, Dr. Elizabeth H. Blackburn;
campaigner and politician Baroness Sally Greengross, and Professor Tom Kirkwood CBE, Dean for Ageing & Director of Newcastle Initiative on Changing Age (NICA) at the University of Newcastle.
Chaired by Lord Robert Winston, Professor of Science and Society and Emeritus Professor of Fertility Studies at Imperial College London, The Astellas Innovation Debate 2013 will explore the role of innovation as society faces critical challenges resulting from an ageing population. The central issues under discussion will be:
- How best can we support older people in the UK and Europe?
- How can we rethink our approach to welfare and healthcare to tackle the major age-associated diseases?
- How will an ageing society be funded, and whose responsibility should it be?
- How can innovation help society value to older people and help older people to make an active contribution?
The aim of the Astellas Innovation Debate 2013 will be to explore, through thought-provoking discussion, whether the scientific ingenuity that played a key role in creating an ageing society can now provide innovative solutions to drive economic and social transformation - turning old age into new age.
For further information, visit our website http://www.innovationdebate.com, or join the debate on Twitter @innovatedebate #AgeCrunch
- Ends -
Notes to editors
The Astellas Innovation Debate is to be chaired by Lord Robert Winston, Professor of Science and Society and Emeritus Professor of Fertility Studies at Imperial College London :
Confirmed panelists include:
Professor John Appleby Chief Economist at the King's Fund since 1998 and a visiting professor at the Department of Economics at City University, London
Dr Elizabeth Blackburn Morris Herzstein Professor in Biology and Physiology in the Department of Biochemistry and Biophysics at the University of California, San Francisco,
Nobel Prize winner in Physiology of Medicine in 2009 and a leader in the area of telomere and telomerase research.
Baroness Sally Greengross A crossbench (independent) member of the House of Lords since 2000 and chair of five All-Party Parliamentary Groups, Chief Executive of the International Longevity Centre (ILC) - UK; Co-President of the ILC Global Alliance.
Professor Tom Kirkwood Dean for Ageing & Director of Newcastle Initiative on Changing Age (NICA) at the University of Newcastle.
About The Astellas Innovation Debate
The Astellas Innovation Debate, organised and funded by Astellas Pharma Europe Ltd., explores the role of innovation in modern society.
This year's event, The Age Crunch: Facts fears and the future, at the Royal Institution of Great Britain on 19th November 2013, is bringing together influential and respected figures from the worlds of science, government, medicine, economics, industry and the media as they tackle the major issues surrounding scientific innovation today and tomorrow. The aim of The Innovation Debate is to air crucial issues, draw positive conclusions and to move the agenda forward.
Everyone - professionals in science, medicine and industry, and the general public - will have the opportunity to engage with The Astellas Innovation Debate through online media which will take discussions far beyond the walls of the Royal Institution of Great Britain.
The inaugural Innovation Debate at The Royal Society in London in November 2012, focused on innovation in a time of austerity and nurturing the innovators of the future. Under the chairmanship of Professor Jim Al-Khalili it brought together panellists such as Nobel laureate Professor Sir Andre Geim, physicist Professor Brian Cox and Professor Mariana Mazzucato, Professor in Economics at the University of Sussex.
About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd., located in the UK, is the European headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 4,350 staff across these regions. For more information about Astellas Pharma Europe, please visit http://www.astellas.eu.
About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd., located in the UK, is the European headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 4,350 staff across these regions. For more information about Astellas Pharma Europe, please visit http://www.astellas.eu.
Share this article